A series of research studies by Edris et al. [242, 243] showed that the anti-KIT monoclonal antibody, SR1, reduced the expression of KIT in tumor cells, strengthened the phagocytotic effect of macrophages and induced tumor cell death; its killing effect was not associated with imatinib sensitivity or resistance [242, 243]. Here, KIT is linked to neoplasm.